Drug Therapy

FDA approves androgen inhibitor for metastatic PCa

September 12, 2012

The FDA recently approved the oral androgen receptor inhibitor enzalutamide (Xtandi) for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel (Taxotere).

Blood test could guide treatment for kidney cancer

August 29, 2012

A common enzyme that is easily detected in blood may predict how well patients with advanced kidney cancer will respond to a specific treatment, according to physicians at Duke Cancer Institute, Durham, NC.

BCG for bladder cancer in short supply

August 22, 2012

Due to manufacturing issues, a formulation of the bladder cancer treatment bacillus Calmette-Guérin is currently unavailable from one manufacturer.

PSA, 5-ARIs help identify hard-to-diagnose PCa

August 22, 2012

Researchers from New York-Presbyterian Hospital/Weill Cornell Medical Center in New York have successfully developed and tested a new prostate cancer screening method.

Drug reduces urge incontinence in OAB patients

August 15, 2012

Fesoterodine fumarate (Toviaz) appears to reduce urge urinary incontinence in patients with overactive bladder who had a suboptimal response to tolterodine tartrate extended release (Detrol LA), according to a phase IV study.

Prostate cancer survival significantly improved with novel radiation agent

August 01, 2012

Interim data from a phase III trial of a novel radiation agent in men with castration-resistant prostate cancer (CRPC) showed the agent's efficacy to be significantly sufficient to bring the trial to a halt at a planned interim analysis so as to be able offer the agent to men in the placebo arm.

Diabetes medication may increase risk of bladder cancer

July 18, 2012

The diabetes drug pioglitazone (Actos) was associated with a 22% increased risk of developing bladder cancer in a recent study, supporting earlier research findings of a link between the drug and bladder cancer.

Companies team up for needle-free botulinum injection platform

July 11, 2012

American Medical Systems (Minnetonka, MN) has signed a co-development agreement with Allergan, Inc. to jointly develop and seek regulatory approval for the delivery of onabotulinumtoxinA (Botox) using the AMS JetTouch system for treatment of overactive bladder.

FDA approves overactive bladder agent with new mechanism of action

July 11, 2012

The FDA has approved the once-daily oral beta-3 adrenergic agonist mirabegron (Myrbetriq) for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

TRT linked with weight loss, improvement of metabolic syndrome symptoms

July 05, 2012

Testosterone replacement therapy may result in weight reduction and improvement in symptoms of metabolic syndrome, according to separate studies presented at the Endocrine Society annual meeting in Houston.

5-alpha-reductase inhibitor use does not compromise PSA utility, study shows

July 01, 2012

Treatment with the dual 5-alpha- reductase inhibitor dutasteride (Avodart) does not compromise the utility of PSA to detect progression of disease in patients with low-risk localized prostate cancer who are being managed with active surveillance.

Investigational agent may boost immune system of kidney Ca patients

June 27, 2012

Two clinical trials testing experimental drugs aimed at restoring the immune system’s ability to spot and attack cancer have shown promising early results in patients with kidney cancer, as well as those with advanced non-small cell lung cancer and melanoma.

Janssen submits supplemental applications for prostate cancer therapy

June 27, 2012

Janssen Research & Development, LLC recently submitted a supplemental new drug application to the FDA for abiraterone acetate (ZYTIGA) intended to extend the use of abiraterone administered with prednisone to include the treatment of patients with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and before chemotherapy.

Investigational prostate Ca agent significantly increases survival

June 20, 2012

The investigational agent radium-223 dichloride significantly increased overall survival in patients with castration-resistant prostate cancer with bone metastases, updated results of a recent phase III trial showed.

More data implicate diabetes agent in increasing bladder cancer risk

June 13, 2012

New data have added to previous evidence that the use of pioglitazone (Actos) appears to be associated with an increased risk of incident bladder cancer among patients with type 2 diabetes, Canadian researchers recently reported.

Adding targeted therapy to hormone therapy may eliminate prostate tumors pre-surgery

June 06, 2012

Six months of treatment with the targeted androgen biosynthesis inhibitor abiraterone (ZYTIGA), in addition to standard hormonal therapy before prostatectomy, eliminated or nearly eliminated cancer in one-third of men with localized high-risk prostate cancer, a recent study found.

High androgen levels linked with advanced prostate cancer survival

June 01, 2012

Elevated pretreatment androgen levels correlate with significantly better overall survival in men with castration-resistant prostate cancer, regardless of treatment, a recent post hoc analysis of a large randomized trial showed.

Phosphodiesterase type-5 inhibitors found safe, efficacious for lower urinary tract symptoms

June 01, 2012

Phosphodiesterase type-5 inhibitors are safe and effective, alone or in combination with alpha-blockers, against lower urinary tract symptoms secondary to BPH, according to a recent systematic review and meta-analysis.

Targeted therapy efficacious in refractory urothelial Ca

June 01, 2012

Three fourths of patients with refractory urothelial cancer had stable disease or better response when treated with the angiogenesis inhibitor pazopanib (Votrient), Italian researchers recently reported.

Opinion split on prescribing phosphodiesterase type-5 inhibitors for pleasure only

June 01, 2012

Physician opinion is divided almost evenly on the question of whether to prescribe phosphodiesterase type-5 inhibitors to patients for non-medical indications, a survey of Israeli doctors showed.